Targovax - Småprat 2020 (TRVX)

[Guny]

Ingen børsmelding fra Targovax🤷‍♂️

[busk1]

De har jo meldt abstractet. Kommer nok ny melding under konferansen 29-31. mai når hele posteren er tilgjengelig.

[InVivo]

Noen som feilet i en lignende indikasjon som Targovax prøver seg på

https://meetinglibrary.asco.org/record/187466/abstract

[TekBot]

Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO

· The abstract describes the dose-escalation part of the ONCOS-102 and
durvalumab combination trial in peritoneal malignancies
· The abstract has been selected for the Poster Discussion Session
…

Vis børsmeldingen

Developmental Therapeutics-Immunotherapy to be presented 29 May at the ASCO 2020
virtual meeting

Oslo, Norway, 14 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing oncolytic viruses to target hard-to-treat solid
tumors, today announces that an abstract relating to the dose escalation part of
the ONCOS-102 and durvalumab trial in primary ovarian and colorectal cancer that
has spread to the peritoneum has been selected for presentation at a Poster
Discussion Session during ASCO 2020.

The study is an open label, exploratory phase I/II trial assessing the intra
-peritoneally delivered ONCOS-102 in combination with systemically administered
checkpoint inhibitor durvalumab in patients with platinum-resistant ovarian or
colorectal cancers that have metastasized to the peritoneal cavity. The trial is
designed with a dose-escalation phase assessing three different dosing levels,
followed by an expansion phase with a total of up to 78 patients enrolled into
separate groups of ovarian and colorectal cancer.

In the ASCO abstract, safety, immune activation and clinical response data for
the three dose escalation cohorts will be presented. A total of 17 patients were
enrolled, 4 in cohort A (low dose), 5 in cohort B (middle dose) and 8 in cohort
C (high dose). No dose-limiting toxicities were observed, and the combination
had an acceptable safety profile. Therefore, the high-dose level was selected
for the expansion phase of the trial, which is currently enrolling patients.
Preliminary analyses indicate that the treatment is triggering immune activation
and has clinical activity, which were more pronounced in cohort B and C.

Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said: “We are very
proud that ONCOS-102 was chosen as the oncolytic virus of choice for this trial
and we are equally pleased that the scientific committee has selected our ONCOS
-102 and durvalumab combination abstract for a poster discussion at the upcoming
ASCO meeting. Although it is too early in the trial to interpret the clinical
data, we are happy to have moved into the expansion phase following successful
completion of the dose escalation phase. This is an important clinical trial as
it addresses a disease with a very high unmet medical need while potentially
opening up intra-peritoneal administration as an alternative delivery route for
ONCOS-102.”

Poster discussion Developmental Therapeutics-ImmunotherapyPhase I/II study
sessionAbstract to evaluate systemic durvalumab + intraperitoneal (IP)
title: ONCOS-102 in patients with peritoneal disease who have
epithelial ovarian (OC) or metastatic colorectal cancer
(CRC): Interim phase I clinical and translational
results.
Date / time: 29 May 2020, 8-11AM CDT
Abstract / Poster: 3017 / 81

The abstract can be found here
https://meetinglibrary.asco.org/record/185276/abstract.

The trial is a collaboration between Targovax, AstraZeneca, Cancer Research
Institute (CRI) and Ludwig Cancer Research.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Kilde

[TekBot]

Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO

· The abstract describes the dose-escalation part of the ONCOS-102 and
durvalumab combination trial in peritoneal malignancies
· The abstract has been selected for the Poster Discussion Session
…

Vis børsmeldingen

Developmental Therapeutics-Immunotherapy to be presented 29 May at the ASCO 2020
virtual meeting

Oslo, Norway, 14 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing oncolytic viruses to target hard-to-treat solid
tumors, today announces that an abstract relating to the dose escalation part of
the ONCOS-102 and durvalumab trial in primary ovarian and colorectal cancer that
has spread to the peritoneum has been selected for presentation at a Poster
Discussion Session during ASCO 2020.

The study is an open label, exploratory phase I/II trial assessing the intra
-peritoneally delivered ONCOS-102 in combination with systemically administered
checkpoint inhibitor durvalumab in patients with platinum-resistant ovarian or
colorectal cancers that have metastasized to the peritoneal cavity. The trial is
designed with a dose-escalation phase assessing three different dosing levels,
followed by an expansion phase with a total of up to 78 patients enrolled into
separate groups of ovarian and colorectal cancer.

In the ASCO abstract, safety, immune activation and clinical response data for
the three dose escalation cohorts will be presented. A total of 17 patients were
enrolled, 4 in cohort A (low dose), 5 in cohort B (middle dose) and 8 in cohort
C (high dose). No dose-limiting toxicities were observed, and the combination
had an acceptable safety profile. Therefore, the high-dose level was selected
for the expansion phase of the trial, which is currently enrolling patients.
Preliminary analyses indicate that the treatment is triggering immune activation
and has clinical activity, which were more pronounced in cohort B and C.

Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said: “We are very
proud that ONCOS-102 was chosen as the oncolytic virus of choice for this trial
and we are equally pleased that the scientific committee has selected our ONCOS
-102 and durvalumab combination abstract for a poster discussion at the upcoming
ASCO meeting. Although it is too early in the trial to interpret the clinical
data, we are happy to have moved into the expansion phase following successful
completion of the dose escalation phase. This is an important clinical trial as
it addresses a disease with a very high unmet medical need while potentially
opening up intra-peritoneal administration as an alternative delivery route for
ONCOS-102.”

Poster discussion Developmental Therapeutics-ImmunotherapyPhase I/II study
sessionAbstract to evaluate systemic durvalumab + intraperitoneal (IP)
title: ONCOS-102 in patients with peritoneal disease who have
epithelial ovarian (OC) or metastatic colorectal cancer
(CRC): Interim phase I clinical and translational
results.
Date / time: 29 May 2020, 8-11AM CDT
Abstract / Poster: 3017 / 81

The abstract can be found here
https://meetinglibrary.asco.org/record/185276/abstract.

The trial is a collaboration between Targovax, AstraZeneca, Cancer Research
Institute (CRI) and Ludwig Cancer Research.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Kilde

[TekBot]

Targovax announces that the ONCOS-102 and durvalumab abstract is selected for a Poster Discussion Session at ASCO

· The abstract describes the dose-escalation part of the ONCOS-102 and
durvalumab combination trial in peritoneal malignancies
· The abstract has been selected for the Poster Discussion Session
…

Vis børsmeldingen

Developmental Therapeutics-Immunotherapy to be presented 29 May at the ASCO 2020
virtual meeting

Oslo, Norway, 14 May 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno
-oncology company developing oncolytic viruses to target hard-to-treat solid
tumors, today announces that an abstract relating to the dose escalation part of
the ONCOS-102 and durvalumab trial in primary ovarian and colorectal cancer that
has spread to the peritoneum has been selected for presentation at a Poster
Discussion Session during ASCO 2020.

The study is an open label, exploratory phase I/II trial assessing the intra
-peritoneally delivered ONCOS-102 in combination with systemically administered
checkpoint inhibitor durvalumab in patients with platinum-resistant ovarian or
colorectal cancers that have metastasized to the peritoneal cavity. The trial is
designed with a dose-escalation phase assessing three different dosing levels,
followed by an expansion phase with a total of up to 78 patients enrolled into
separate groups of ovarian and colorectal cancer.

In the ASCO abstract, safety, immune activation and clinical response data for
the three dose escalation cohorts will be presented. A total of 17 patients were
enrolled, 4 in cohort A (low dose), 5 in cohort B (middle dose) and 8 in cohort
C (high dose). No dose-limiting toxicities were observed, and the combination
had an acceptable safety profile. Therefore, the high-dose level was selected
for the expansion phase of the trial, which is currently enrolling patients.
Preliminary analyses indicate that the treatment is triggering immune activation
and has clinical activity, which were more pronounced in cohort B and C.

Dr. Magnus Jäderberg, Chief Medical Officer of Targovax, said: “We are very
proud that ONCOS-102 was chosen as the oncolytic virus of choice for this trial
and we are equally pleased that the scientific committee has selected our ONCOS
-102 and durvalumab combination abstract for a poster discussion at the upcoming
ASCO meeting. Although it is too early in the trial to interpret the clinical
data, we are happy to have moved into the expansion phase following successful
completion of the dose escalation phase. This is an important clinical trial as
it addresses a disease with a very high unmet medical need while potentially
opening up intra-peritoneal administration as an alternative delivery route for
ONCOS-102.”

Poster discussion Developmental Therapeutics-ImmunotherapyPhase I/II study
sessionAbstract to evaluate systemic durvalumab + intraperitoneal (IP)
title: ONCOS-102 in patients with peritoneal disease who have
epithelial ovarian (OC) or metastatic colorectal cancer
(CRC): Interim phase I clinical and translational
results.
Date / time: 29 May 2020, 8-11AM CDT
Abstract / Poster: 3017 / 81

The abstract can be found here
https://meetinglibrary.asco.org/record/185276/abstract.

The trial is a collaboration between Targovax, AstraZeneca, Cancer Research
Institute (CRI) and Ludwig Cancer Research.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Kilde

[Teddy1]

Preliminary analyses indicate that the treatment is triggering immune activation
and has clinical activity, which were more pronounced in cohort B and C.

Lovende!

[InVivo]

Blir spennende å se posteren som kommer om 2 uker. Cut off var jo i november 2019, snart 6 mnd siden. Kan påvirke OS en hel del

[Teddy1]

Jepp, fortsatt to i live. La oss håpe de får leve en stund til.

Two patients remained on treatment at data cutoff.

[Cinvest]

A total of 17 patients were
enrolled, 4 in cohort A (low dose), 5 in cohort B (middle dose) and 8 in cohort
C (high dose). No dose-limiting toxicities were observed, and the combination
had an acceptable safety profile. Therefore, the high-dose level was selected
for the expansion phase of the trial, which is currently enrolling patients.
Preliminary analyses indicate that the treatment is triggering immune activation
and has clinical activity, which were more pronounced in cohort B and C.

Veldig fint. Da ser vi litt av samme retningen her som for Melanoma. Høyere dosering trigger høyere immunaktivering og klinisk aktivitet som det refereres til her. Kan jo love godt også for Melanom studien som de allerede har forespeilet at de tror.

[InVivo]

Hvem skal ha med et virus i denne studien videre?

Partner på mesothelioma er nok AZ

https://meetinglibrary.asco.org/record/184552/abstract

[Guny]

Da kan Targovax levere gratis oncos😁 Det får holde👍

[TheObserver]

TRVX: SKAL PRESENTERE KOMBINASJONSSTUDIE PÅ ASCO 2020, FOKUS PÅ DE ULIKE DOSERINGSKOHORTENE

Oslo (TDN Direkt): Targovax skal presentere et sammendrag om kombinasjonsstudien som vurderer ONCOS-102 og sjekkpunkthemmeren durvalumab for behandling av kreft med spredning til bukhinnen på ASCO 2020 den 29. mai. Pasientene i studien har livmorhalskreft eller endetarmskreft med spredning til bukhinnen.

Det fremgår av en melding fra selskapet torsdag.

Det er de ulike doseringskohortene som er fokus for denne presentasjonen.

• Vi er veldig stolt over at ONCOS-102 ble valgt som det onkolytiske viruset for denne studien, og glade for at den er plukket ut for å diskuteres på den største konferansen for kreftforskning i USA - ASCO. Selv om det er for tidlig i studien til å tolke kliniske data, er vi fornøyd med at studien går videre med høyeste dose, sier Dr. Magnus Jäderberg, medisinsk direktør i Targovax i en pressemelding.

I ASCO-sammendraget vil bivirkningsprofil, immunaktiveringsdata og data som viser klinisk respons for de tre ulike doseringskohortene bli presentert. Totalt har 17 pasienter deltatt i studien. Fire i kohort A - lav dose, fem i kohort B - medium dose og åtte i kohort C - høy dose. Det ble ikke observert bivirkninger som begrenset dosen, og behandlingen ble funnet å ha akseptabel sikkerhetsprofil. Derfor ble doseringen i kohort C - høy dose valgt for utvidelsen av studien. Innrullering av pasienter til denne delen pågår. Foreløpige analyser indikerer at behandlingen med medium og høy dose aktiverer immunsystemet og gir klinisk effekt, opplyser Targovax i meldingen.

• Dette er en viktig studie fordi den retter seg mot en pasientgruppe med store, udekkete behov for medisinsk behandling. For oss gir den også mulighet for å teste injeksjon av ONCOS-102 i bukhulen som en alternativ administrasjonsmetode, sier Jäderberg i pressemeldingen.

SSN finans@tdn.no

[aborum]

Jeg havde fat i Renate Birkeli fra IR denne morgen vedr. manglende melding på deres abstrakt. Muligt IR noterede sig dette request og handlede prompte, eller også var det et spørgsmål om timing.

Som forventet viser dose eskaleringen, at højere dose giver højere aktivitet. Her er vejen banet for adgang til en population af patienter, der svært mangler effektive behandlingsmuligheder.

Benærk dog at det er relativt tidligt i studiet og data, baseret på ovenstående observationer, må forventes at bedres betydeligt (dvs. et allerede lovende “signal of efficacy” forventes at blive til “proof of efficacy”, i hvert fald af undertegnede).

Endnu engang viser ONCOS til lav eller ingen toksisitet og databasen vokser dag for dag med bevis om, at TRVX virus er sikkert i kombination med alt, der meningsfuldt kan tilbydes patienterne af behandling.

[InVivo]

Trekker man fra de 4 som lav dose med virus, så kan DCR plutselig se veldig, veldig bra ut!

Tidlig stadie, men veldig lovende funn

[Dataminer]

Så vi har i Meso:

Oncos + Pem/Cis:

• safety ok
• robust immune activation
• positive
  association between immune response and clinical outcome

Durvalumab + Pem/Cis:

• safety ok
• the combination of chemotherapy with durvalumab delivered a promising median OS

Trippelstudiet:
Chemo + OV + CPI =
Pem/Cis + Oncos + Durvalumab=

TRVX + AZ

AZ, som har vært hemmelig BP-partner for PCIB frem til årsskiftet og som nå sitter i forhandlinger med PCIB om veien videre, dukker altså opp også her.

NICE

[ge-ge]

Jeg havde fat i Renate Birkeli fra IR denne morgen vedr. manglende melding på deres abstrakt. Muligt IR noterede sig dette request og handlede prompte, eller også var det et spørgsmål om timing.

Er du sprøyte pine gal Aborum? Alle vet jo hva som skjer med kursen når det sendes ut meldinger fra norsk biotek!

[InVivo]

SELL ON NEWS!

Når skal selskapene lære? Bedre å bare holde kjeft, så kan markedet spekulere som ville helvete

[Cinvest]

Tidlig stadie, men veldig lovende funn

Poster Discussion Sessions : Each track-based Poster Discussion Session will be 90 minutes in length and will highlight 12 abstracts from the Poster Session held earlier in the day. Four invited discussants will each provide a 12-minute discussion placing the selected abstracts in context, with a focus on how the findings apply to clinical practice and future research.

Dette mener tydeligvis komiteen på ASCO også…

[Morgo26]

If only Oslo Børs thought the same…